Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HRS9531 tablets in overweight or obese adults
CTR20262454Phase 3Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jul 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of HRS9531 in obesity, Overweight, sponsored by Fujian Shengdi Pharmaceuticals. Started Jul 2026; status: active.
02
Drugs
HRS9531
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20262454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262454.